Study average: what results can tell you.

In SURMOUNT-1, the average loss for adults who did not have diabetes was about 15–21% of their starting weight over 72 weeks.

Those receiving a dummy shot lost about 3%.

The result varied with the medicine strength used in the study.

A dummy shot, also called a placebo, has no active study medicine.

These adults had obesity, meaning a high level of excess body weight, or overweight with a related health problem.

Participants had regular study visits and help with food and activity changes. The drug maker funded the study.

Ask how the proposed care and your own health differ from the study.

In SURMOUNT-4, people who switched to a dummy shot after 36 weeks gained an average of 14% over the next 52 weeks, measured from their weight at the switch.

The comparison starts when they switched, after losing weight on treatment; it is not a share of the weight they had lost.

People who continued tirzepatide lost an average of another 5.5% over those 52 weeks, also measured from their weight at the switch.

This is a study result, not a rule that everyone must continue treatment.

Ask how care, costs and a stopping plan would work for you.

On September 26, 2026, the drug maker’s terms listed Zepbound (tirzepatide) at $299–$699 per 28-day supply for vials and KwikPen.

Vials are small medicine bottles; the KwikPen holds several injections.

The $449 offer for higher strengths required a refill within 45 days of the previous delivery.

The recorded offer terms run through December 31, 2026.

The source record is the maker’s Zepbound savings terms and self-pay price page.

The government price directory shows a starting price, not the full range for every strength.

Request the exact written price for the product in the offer you are considering.